Different Roles for Colony Stimulating Factor 1 Isoforms in Anabolic Therapy for Low Bone Mass
集落刺激因子 1 同工型在低骨量合成代谢治疗中的不同作用
基本信息
- 批准号:10585240
- 负责人:
- 金额:$ 65.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-10 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffinityAgonistAnabolismAnimal ModelAnimalsAttenuatedB-LymphocytesBindingBone ResorptionC57BL/6 MouseCSF1 geneCSF1R geneCellsCoculture TechniquesColony-Stimulating FactorsDataDoseEnzymesEstrogen deficiencyEventExposure toImmunophenotypingImpairmentIn VitroKineticsMacrophage Colony-Stimulating FactorMembraneModelingMolecularMusOsteoblastsOsteoclastsOsteogenesisOsteoporosisParacrine CommunicationPatientsPhospholipidsPopulation StudyPostmenopausal OsteoporosisProductionProtein IsoformsRegimenRoleSerumSignal TransductionT-LymphocyteTestingTherapeuticTimeTreatment EfficacyTreatment ProtocolsWild Type Mousebonebone lossbone massdensityexperimental studyin vivoin vivo Modelinhibitorinsightmouse modelnew therapeutic targetnovelosteoclastogenesisparacrinepharmacologicpre-clinicalreceptorresponseskeletalskeletal disordersphingosine 1-phosphatesphingosine kinasetranscriptometranscriptome sequencingtranscriptomic profiling
项目摘要
CSF1 is the principal colony stimulating activity released by osteoblasts in response to PTH treatment. Its
receptor, c-fms, is more highly expressed on mature osteoclasts than any other cell in bone. We found that
deleting c-fms in osteoclasts attenuates the anabolic response to PTH. This indicates that part of PTH's anabolic
actions could be via a paracrine loop in which PTH stimulates expression of CSF1 in osteoblasts, which then
acts on osteoclasts to induce anabolic clastokines that augment bone formation. There are two major isoforms
of CSF1: soluble (sCSF1) and membrane-associated (mCSF1). We found that the anabolic response to PTH
is augmented in animals only expressing the sCSF1 isoform due to a greater increase in osteoblast
number in these mice compared to PTH-treated controls. In striking contrast, animals only expressing
mCSF1 had no increase in bone mass in response to an anabolic PTH regimen. Importantly, sCSF1 and
mCSF1 differ in the kinetics and extent to which they activate the CSF1 receptor, c-fms, suggesting that their
divergent in vivo actions may be due in part, to intrinsic differences in cell-signaling. Based on these data, we
hypothesize that mCSF1 inhibits PTH anabolism by opposing the actions of sCSF1 on osteoclasts. When
unopposed, sCSF1 contributes to PTH anabolism by inducing production of anabolic clastokines.
Specifically, single daily doses of PTH induce transient increases in sCSF1 in osteoblasts that cause
bursts of anabolic clastokine production. Consistent with this, we found that sCSF1 stimulates production of
the anabolic clastokine, sphingosine-1-phosphate (S-1-P) in osteoclasts. To test these hypotheses, we will, in
SA1, determine if adding intermittent dosing of sCSF1 to an anabolic PTH treatment regimen augments
the skeletal response to PTH in wild type animals, while adding mCSF1 to that regimen attenuates the
response. We will then try to restore the anabolic response to PTH in the sCSF1-/- mice by treating with PTH
plus sCSF1. These experiments will provide pharmacologic evidence that the very different response to PTH in
sCSF1-/- and mCSF1-/- mice is directly due to differing actions of the two CSF1 isoforms in bone. In SA 2, we
will treat wild type mice that were ovariectomized 5 months earlier, with PTH plus sCSF1 to determine if
it restores bone mass to pre-OVX levels as a model of therapy for established post-menopausal
osteoporosis. In SA 3, we will determine if sCSF1 and mCSF1 induce production of different clastokine
profiles in mature osteoclasts. We will use osteoblast/osteoclast cocultures as a model of in vivo paracrine
signaling in bone and profile the transcriptome of osteoclasts exposed to PTH-treated osteoblasts expressing
only sCSF1 or only mCSF1 to identify differences in the types of clastokines produced. We will also determine
differences in the transcriptomes of osteoblasts in the cocultures stimulated by these different clastokine profiles.
Finally, we will examine binding kinetics of sCSF1 and mCSF1 to c-fms, and differences in downstream signaling,
to gain molecular insight into the divergent in vivo and in vitro actions of these two isoforms.
CSF1是成骨细胞在甲状旁腺素治疗后释放的主要集落刺激活性。它的
C-FMS受体在成熟的破骨细胞上的表达比骨骼中的任何其他细胞都高。我们发现
在破骨细胞中删除c-fms可减弱对甲状旁腺素的合成代谢反应。这表明甲状旁腺素的部分合成代谢
作用可能是通过旁分泌环,其中PTH刺激成骨细胞中CSF1的表达,然后
作用于破骨细胞,诱导促进骨形成的同化破骨因子。有两种主要的亚型
CSF1:可溶性(SCSF1)和膜结合(MCSF1)。我们发现对甲状旁腺素的合成代谢反应
在仅表达sCSF1亚型的动物中由于成骨细胞的较大增加而增强
在这些小鼠中与PTH处理的对照组进行比较。与之形成鲜明对比的是,动物只表达
MCSF1对合成代谢甲状旁腺素方案没有增加骨量。重要的是,sCSF1和
MCSF1在激活CSF1受体c-fms的动力学和程度上有所不同,这表明他们的
体内作用的不同可能部分是由于细胞信号的内在差异。根据这些数据,我们
假设mCSF1通过对抗sCSF1对破骨细胞的作用而抑制PTH合成代谢。什么时候
非相反,sCSF1通过诱导合成的碎裂因子的产生而促进PTH的合成代谢。
特别是,每天单次剂量的甲状旁腺素诱导成骨细胞中sCSF1的一过性增加,从而导致
一连串合成代谢的碎裂因子产生。与此一致,我们发现sCSF1刺激了
破骨细胞中合成的破骨细胞因子-1-磷酸鞘氨醇(S-1-P)。为了检验这些假设,我们将在
SA1,确定在合成代谢甲状旁腺激素治疗方案中加入间歇剂量的sCSF1是否会增加
野生型动物对甲状旁腺素的骨骼反应,同时在该方案中加入mCSF1可减弱
回应。然后,我们将尝试通过PTH治疗来恢复sCSF1-/-小鼠对PTH的合成代谢反应
加上sCSF1。这些实验将提供药理学证据,证明对甲状旁腺素的不同反应
SCSF1-/-和mCSF1-/-小鼠是由于两种CSF1亚型在骨骼中的不同作用直接造成的。在SA 2中,我们
将用PTH加sCSF1治疗5个月前切除卵巢的野生型小鼠,以确定是否
它将骨量恢复到去卵巢前的水平,作为绝经后的治疗模式
骨质疏松。在SA 3中,我们将确定sCSF1和mCSF1是否诱导产生不同的clastokine
成熟破骨细胞的特征。我们将使用成骨细胞/破骨细胞共培养作为体内旁分泌的模型。
骨信号转导与甲状旁腺素作用下破骨细胞转录组的表达
仅使用sCSF1或仅使用mCSF1来识别产生的碎裂因子类型的差异。我们还将确定
在这些不同的碎裂因子谱刺激的共培养中,成骨细胞转录本的差异。
最后,我们将研究sCSF1和mCSF1与c-fms的结合动力学,以及下游信号转导的差异,
从分子水平深入了解这两种异构体在体内和体外的不同作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KARL Leonard INSOGNA其他文献
KARL Leonard INSOGNA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KARL Leonard INSOGNA', 18)}}的其他基金
An ounce of prevention: stopping menopausal bone loss before it starts
一盎司的预防:在更年期骨质流失开始之前阻止它
- 批准号:
10324591 - 财政年份:2021
- 资助金额:
$ 65.93万 - 项目类别:
The Role of Sphingosine Kinases in Bone Anabolism
鞘氨醇激酶在骨合成代谢中的作用
- 批准号:
9274156 - 财政年份:2016
- 资助金额:
$ 65.93万 - 项目类别:
A novel SATB2 mutation illuminates bone anabolism
一种新的 SATB2 突变阐明了骨合成代谢
- 批准号:
8874913 - 财政年份:2014
- 资助金额:
$ 65.93万 - 项目类别:
A novel SATB2 mutation illuminates bone anabolism
一种新的 SATB2 突变阐明了骨合成代谢
- 批准号:
8758799 - 财政年份:2014
- 资助金额:
$ 65.93万 - 项目类别:
Calcitonin for Treating X-linked Hypophosphatemia
降钙素治疗 X 连锁低磷血症
- 批准号:
8319251 - 财政年份:2011
- 资助金额:
$ 65.93万 - 项目类别:
Calcitonin for treating X-linked hypophosphatemia
降钙素治疗 X 连锁低磷血症
- 批准号:
8193343 - 财政年份:2011
- 资助金额:
$ 65.93万 - 项目类别:
Conditional Deletion of PTHrP in Articular Chondrocytes
关节软骨细胞中 PTHrP 的条件性缺失
- 批准号:
7609121 - 财政年份:2008
- 资助金额:
$ 65.93万 - 项目类别:
Conditional Deletion of PTHrP in Articular Chondrocytes
关节软骨细胞中 PTHrP 的条件性缺失
- 批准号:
7509044 - 财政年份:2007
- 资助金额:
$ 65.93万 - 项目类别:
Microcomputed tomography device (Scanco microCT35)
微型计算机断层扫描设备(Scanco microCT35)
- 批准号:
7389328 - 财政年份:2007
- 资助金额:
$ 65.93万 - 项目类别:
IMPACT OF A PROTEIN SUPPLEMENT ON BONE MASS IN OLDER WOMEN
蛋白质补充剂对老年女性骨量的影响
- 批准号:
7194429 - 财政年份:2006
- 资助金额:
$ 65.93万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 65.93万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 65.93万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 65.93万 - 项目类别:














{{item.name}}会员




